Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.49 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.48 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.48 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | FAP | Q12884 | 1/20 | 0.45 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6739912 | 1.00 | DPP4 (0.49) | DPP4GRM1SLC22A2SLC47A1ALDH1A1 | |
| SCHEMBL23460047 | 1.00 | DPP4 (0.49) | DPP4GRM1SLC22A2SLC47A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28561376 | 0.98 | ALDH1A1 (0.50) | DPP4GRM1SLC22A2SLC47A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28561377 | 0.98 | ALDH1A1 (0.50) | DPP4GRM1SLC22A2SLC47A1ALDH1A1 | |
| SCHEMBL25661411 | 0.91 | GRM1 (0.52) | DPP4GRM1SLC22A2SLC47A1ALDH1A1 | |
| SCHEMBL18650239 | 0.91 | GRM1 (0.52) | DPP4GRM1SLC22A2SLC47A1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL18631597 | 0.88 | GRM1 (0.50) | DPP4GRM1ALDH1A1ALOX15MAPT | |
| Hydrochloric Acid SCHEMBL18631596 | 0.86 | GRM1 (0.48) | DPP4GRM1ALDH1A1ALOX15FAP | |
| SCHEMBL18397921 | 0.82 | ALDH1A1 (0.50) | DPP4SLC22A2SLC47A1ALDH1A1ALOX15 | |
| SCHEMBL255450 | 0.81 | DPP4 (0.63) | DPP4GRM1FAPPITRM1DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112679369-B | Preparation method of (S) -2- (adamantane-1-yl) -2-glycine hydrochloride | 南通药明康德医药科技有限公司 | 2022-07-15 | — | — | CN | claimed |
| CN-112679369-A | Preparation method of (S) -2- (adamantane-1-yl) -2-glycine hydrochloride | 南通药明康德医药科技有限公司 | 2021-04-20 | — | — | CN | claimed |
| US-12637414-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| CN-119816491-A | New spirocyclohexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2025-04-11 | — | — | CN | disclosed |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIB VZW (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIB VZW (BE) | 2024-01-16 | — | — | US | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| US-20230357307-A1 | CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING | ILLUMINA, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357307-A1 | CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING | ILLUMINA, INC. | 2023-11-09 | — | — | US | disclosed |
| EP-0670729-A4 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS. | CEPHALON INC (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0647629-A1 | Neurotensin active substituted 1-naphthylpyrazole-3-carboxamides, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1995-04-12 | — | — | EP | disclosed |
| EP-0604605-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1994-07-06 | — | — | EP | disclosed |
| WO-1993020836-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993008826-A1 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1993-05-13 | — | — | WO | disclosed |
| EP-0476044-A4 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | — | 1992-07-01 | — | — | EP | disclosed |
| EP-0476044-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS. | CEPHALON INC (US) | 1992-03-25 | — | — | EP | disclosed |
| US-5093317-A | Amyotrophic Lateral Sclerosis | CEPHALON, INC. (US) | 1992-03-03 | — | — | US | disclosed |
| WO-1990014838-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1990-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637414-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, ABCC1 | DPP4 1478/4885GRM1 2704/4885SLC22A2 754/4885 |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | DPP4 3671/4885GRM1 2758/4885SLC22A2 4257/4885 |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIP, MMP8, SLC11A2 | DPP4 150/4885GRM1 4479/4885SLC22A2 2823/4885 |
| US-20230357307-A1 | CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING | TENT4A, TENT4B, DNTT | DPP4 637/4885GRM1 4780/4885SLC22A2 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.